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ABSTRACT
ASSESSMENT OF URINARY METHYLMALONIC ACID LEVELS IN OLDER ADULTS
ON PROTON PUMP INHIBITORS
Tashia Sue Warner, M.S.
School of Family, Consumer and Nutrition Sciences
Northern Illinois University, 2015
Judith Lukaszuk, Thesis Chair

Background: Proton pump inhibitors (PPIs) affect gastric acid secretion. The use of PPIs in the
elderly population (>70 years old) may increase the risk of vitamin B12 deficiency because
gastric acid is needed for vitamin B12 digestion and absorption. However, it’s unclear whether
adults ages 50-70 years old who use PPIs chronically are at risk of vitamin B12 deficiency.
Objective: To determine whether chronic use of PPIs results in increased urinary methylmalonic
acid (uMMA) levels in adults ages 50-70 years old, indicating vitamin B12 deficiency.
Methods: Fifteen men and women who had been taking PPIs daily for a minimum of one year
were recruited. Fifteen subjects, not taking PPIs, were age-matched (± 3 years) and gendermatched to the subjects taking PPIs. Tissue stores of vitamin B12 were determined using uMMA.
Results: There were no significant differences in uMMA levels between those taking PPIs (Mdn
= 1.60 µg uMMA/mg creatinine) and those not taking PPIs (Mdn = 1.80 µg uMMA/mg
creatinine) (p = 0.12).
Conclusion: Chronic use of PPIs did not alter vitamin B12 status of subjects in healthy adults
ages 50-70 years old. Regular monitoring of vitamin B12 status does not appear to be needed in
this age group; however studies using larger groups are indicated to confirm these findings.

NORTHERN ILLINOIS UNIVERSITY
DEKALB, ILLINOIS

DECEMBER 2015

ASSESSMENT OF URINARY METHYMALONIC ACID LEVELS IN OLDER ADULTS ON
PROTON PUMP INHIBITORS

BY
TASHIA SUE WARNER
©2015 Tashia Sue Warner

A THESIS SUBMITTED TO THE GRADUATE SCHOOL
IN PARTIAL FULFILLMENT OF THE REQUIREMENTS
FOR THE DEGREE
MASTER OF SCIENCE

DEPARTMENT OF FAMILY, CONSUMER AND NUTRITION SCIENCES

Thesis Chair:
Judith Lukaszuk

ACKNOWLEDGEMENTS

Due to their help and support throughout this entire process, I would like to thank Dr.
Lukaszuk, Dr. Umoren, Dr. Shokrani and Dr. Prawitz. These individuals served on the thesis
committee, except Dr. Prawitz, and provided guidance and support along the way to thesis
completion. Dr. Lukaszuk has been an incredible mentor and has been instrumental in the
completion of this research. Dr. Shokrani has been a great resource in regards to edits and
revisions, and he also allowed for the storage of specimens in the freezer in Dusable Hall for
future testing. Dr. Umoren provided access to NutriCalc, thus allowing for diet analysis to be
completed. Dr. Prawitz provided guidance and assistance regarding statistical analysis. Without
her help, the data analysis would not have been possible.
The College of Health and Human Sciences provided financial assistance via the Dean’s
Research Grant. This grant made this research financially feasible and I would like to express my
gratitude for the monetary award.

TABLE OF CONTENTS

Page
LIST OF TABLES…………………………………………………………..……. vi
LIST OF FIGURES………………………………………………………………. vii
LIST OF APPENDICES…………………………………………………………. viii
Chapter
1. INTRODUCTION………………………………………………………… 1
Background…………………………………………………..…………… 1
Justification……………………………………………………………….. 3
Statement of the Problem…………………………………………………. 4
Hypothesis………………………………………………………………...

4

2. REVIEW OF LITERATURE…………………………………………….. 5
Vitamin B12…….………………………………………..……………….... 5
Dietary and Supplemental Sources……………...…….…………... 5
Functions and Biochemistry……………………………………..... 6
Absorption, Metabolism and Storage………………...…………… 9
At-Risk Populations for Deficiency……………...……………….. 10
Causes of Deficiency……………………………………………… 11
Signs and Symptoms of Deficiency………………………….…… 14
Biomarkers………………………………….……………………. 16

iv
Chapter

Page
Prevalence of Deficiency in the Aging Population…………….… 19

Proton Pump Inhibitors…………….………………………………….…. 20
Indications and Uses…………………………………………...…. 20
Mechanism of Action…………………………………………..…. 21
Potential Side Effects…………………………………………..…. 22
Nutritional Deficiencies – Vitamin B12………………....… 22
Rebound Acid Hypersecretion………………………….… 23
Relationship Between PPI Use and Vitamin B12…………………………. 23
Conclusion ….....…………………………………….…………………… 28
3. METHODS………………………………………………………………. 30
Selection of the Sample...………………………………………………... 30
Data Collection…….…………………………………………………..…. 31
Instruments…...………………………………….……………………….. 31
Survey…………………………………………………………….. 31
Diet Analyses……………….………………………………….…. 32
Anthropometrics………………………………………………….. 32
Urine Samples………………………………………….…………. 32
Laboratory Measurements………………………………………… 33
Data Analysis...….…………………………………….………………….. 33
4. RESULTS………………………………………………………………… 35
Research Methodology………………………………….………………… 35
Participants……………………………….….………….………………… 35

v
Chapter

Page
General Characteristics………………………………………...…. 35
Physical Activity………………….………………………………. 36
Details Regarding PPI Use……………………………..……….… 36

Equivalency of Groups……………………….……………………….…... 37
Physical Characteristics………………..…………………………. 37
Dietary Intake……………………………………….……………. 38
Supplemental Intake………………………………………...……. 40
Urinary Methylmalonic Acid……………….…………………..... 42
5. DISCUSSION………………………………………………………….…. 44
Physical Characteristics….………………………………………………. 45
Dietary and Supplemental Intake…...………………….…………….…..

45

Urinary Methylmalonic Acid…………..………………………………...

46

Conclusion……………………………………………………………….

46

6. LIMITATIONS AND FUTURE RESEACH…………………………….. 47
Limitations………………………………………………………………... 47
Future Research………………………………………………………….... 48
REFERENCES………………………………………………………………….... 49
APPENDICES……………………………………………………………………. 54

LIST OF TABLES

Table
1. Physical Characteristics of PPI Users and Non-PPI Users………………

Page

37

2. Dietary Intake of PPI Users and Non-PPI Users…………………….…... 39
3. Supplemental Intake of PPI Users and Non-PPI Users………………...... 41
4. Urinary Methylmalonic Acid Levels of
PPI Users and Non-PPI Users……………………………………..…….

43

LIST OF FIGURES

Figure

Page

1. Conversion of homocysteine to methionine………………………..…..

7

2. Formation of succinyl-CoA…………………………………………….

8

3. Physical characteristics of PPI users and non-PPI users……………….

38

4. Dietary intake of PPI users and non-PPI users…………………………

39

5. Dietary intake of folate of PPI users and non-PPI users……………….

40

6. Supplemental intake of PPI users and non-PPI users………..…………

41

7. Supplemental intake of folic acid of
PPI users and non-PPI users…………………………………………….

42

8. Urinary methylmalonic acid levels of
PPI users and Non-PPI users………………………………………….....

43

LIST OF APPENDICES

Appendix

Page

A.

RECRUITMENT FLYERS…………………………………………...…... 54

B.

RECRUITMENT SCRIPT……………………………………………….. 57

C.

RECRUITMENT SCREENING FORM……………………...………….. 62

D.

IRB APPLICATION AND APPROVAL LETTER………….……..……. 64

E.

IBC APPLICATION AND APPROVAL LETTER.…………………….. 75

F.

CONSENT FORM……………..………….…………………………..….. 82

G.

THREE-DAY FOOD LOG………………………………………………. 84

H.

SURVEY FOR PPI USERS……………...……………………………….. 89

I.

SURVEY FOR NON-PPI USERS…………………….…………………. 93

CHAPTER 1
INTRODUCTION

Background

In the United States (U.S.), adults over 65 years of age comprise 13.7% of the
population.1 This is the equivalent of 43.1 million people.1 This is a 21% increase since 2002
and more than triple the older adult population since 1900.1 While this population has increased,
another population group is steadily growing, and between 2002 and 2012, Americans ages 4564 years old have increased by 24%.1 The aging population often suffers from at least one
chronic condition or possibly multiple co-morbidities including gastrointestinal issues. One
common condition, affecting between 6-17% of the U.S. elderly population, is gastroesophageal
reflux disease (GERD).2 A common medication for GERD is a proton pump inhibitor (PPI). PPIs
act by binding the hydrogen potassium ATPase pump of the parietal cells, thereby inhibiting
gastric acid secretion from these cells in the stomach.3 This lack of gastric acid is thought to have
adverse effects on the absorption of vitamin B12 bound to food sources since stomach acid is
required to break the vitamin B12/protein bonds. These bonds must be broken in order for vitamin
B12 to become available for absorption. The elderly are prone to additional gastric problems that
may also decrease their ability to absorb nutrients.4
As much as 11-50% of the elderly population is thought to have chronic atrophic
gastritis.5 Atrophic gastritis results in malabsorption of vitamin B12 as well as other nutrients.5
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Since vitamin B12 is vital for neurological functions, a deficiency may contribute to cognitive
decline that is often seen in the elderly population. Vitamin B12 deficiency is a common problem
in the elderly. According to the data from the National Health and Nutrition Examination
Surveys from 1999 to 2002, serum vitamin B12 deficiency was seen in approximately 4% of
people aged 40-59 years old and 6% of people > 70 years old.6,7 Marginal status was even more
common and occurred in approximately 14-16% of individuals ages 20-59 years old and >20%
of individuals greater than 60 years old.6 Deficiency is very unlikely to be linked to lack of
dietary intake even within this vulnerable population and malabsorption is considered the most
common culprit of vitamin B12 depletion.8 Currently, there are no standards for screening at-risk
individuals for vitamin B12 deficiency although some sources recommend a vitamin B12
supplement >50 µg/day to prevent a deficiency in the elderly.8,9 However, 50 µg/day would not
be sufficient to replete levels for a person already suffering from a moderate vitamin B12
deficiency.8 Even if widespread screening was implemented, identifying vitamin B12 deficiency
in this population would be difficult, costly, and the current biomarkers that are utilized may not
be the most sensitive or precise indicators.
Most studies have evaluated serum vitamin B12 or serum methylmalonic acid (sMMA) to
determine vitamin B12 status, yet there are limitations to both of these biomarkers.10,11 Research
indicates that serum vitamin B12 and sMMA may be flawed in identifying vitamin B12 status
because serum levels of vitamin B12 and MMA may remain stable while tissue stores of vitamin
B12 are deficient, whereas urinary methylmalonic acid (uMMA) can assess acute tissue stores of
vitamin B12.10 uMMA can be easily measured in the urine and is one of the earliest and most
precise markers indicative of vitamin B12 tissue depletion.8,11 Only one study has utilized uMMA
to determine vitamin B12 status in younger individuals (20-50 years old) and did not find a
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difference in uMMA between PPI users and non-PPI users. Typical biomarkers used to
evaluate vitamin B12 status may not be sensitive enough to identify an early deficiency and thus
prevent the occurrence of irreversible neurological symptoms.13 uMMA has an overall greater
sensitivity and specificity than other biomarkers, including sMMA, and should be considered a
functionally relevant biomarker of acute tissue stores of vitamin B12.11,14
The current body of research regarding vitamin B12 absorption and PPI use in the elderly
has shown conflicting results. A study analyzing uMMA in the younger population using PPIs
did not find any significant differences in uMMA values.12 Some studies in the elderly using
serum vitamin B12 as the biomarker have shown no effect of PPIs on vitamin B12 status.15,16 In
contrast, other studies analyzing PPI use in the elderly show a decreased level of serum vitamin
B12 compared to non-PPI users.17-19 The current research has also primarily focused on
individuals >65 years old or <50 years old, ignoring the aging population between 50-65 years
old. A majority of the current research used serum vitamin B12 to detect a vitamin B12 deficiency,
and serum vitamin B12 may miss a significant proportion of the population that may be deficient
or have suboptimal vitamin B12 status. No studies have analyzed uMMA in the aging or elderly
population, likely due to the high cost of testing for uMMA. This research will investigate
whether PPI use results in vitamin B12 deficiency when using the biomarker uMMA in the 50-70year-old adult population.

Justification

The older adult population will continue to grow due to increased life expectancy, and by
2030 roughly 20% of the U.S. population will be comprised of older adults > 65 years old.1
Adults over the age of 50 years old are more prone to developing GERD and as such are
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commonly prescribed PPIs for long-term use. The adverse effects of PPIs have been reported,
but studies are often inconclusive and long-term effects of PPI treatment remain largely
unknown.3,15,17,18,20-22 Vitamin B12 deficiency can be a very serious condition leading to
irreversible neurological damage, cognitive impairment, and dementia.13 In addition, vitamin B12
malabsorption may be further exacerbated by age-related gastric changes (i.e. hypochlorhydria)
in the aging adult population.4,8 Cognitive function in the elderly, as well as the aging population,
is important and it may be markedly improved by providing a vitamin B12 supplement, should a
deficiency be detected.

Statement of the Problem

The purpose of this investigation is to determine if aging adult PPI users have a greater
occurrence of deficiency of vitamin B12, as determined through uMMA, versus non-PPI users.
The independent variable is the utilization of PPIs in older adults ages 50-70 years old. This
includes both PPI users and non-PPI users. The dependent variable is the uMMA levels of both
the PPI users and non-PPI users.

Hypothesis

It is hypothesized that adult PPI users will have higher uMMA levels, indicating a
vitamin B12 deficiency, versus non-PPI users.

CHAPTER 2
REVIEW OF LITERATURE

Vitamin B12

Dietary and Supplemental Sources

Vitamin B12, also known as cobalamin, is a water-soluble vitamin endogenously
synthesized by intestinal bacteria. However, endogenous synthesis alone in humans is not
sufficient, so exogenous vitamin B12 intake is essential to meet required needs.8 Rich sources of
vitamin B12 include organ meats (i.e. liver and kidney), poultry, fish, shellfish, mushrooms, eggs,
milk and dairy products.8,23 Grain and cereal products, despite being of plant origin, are good
sources of vitamin B12 due to fortification practices in the U.S.23 The fortification of various food
items allows one to meet the daily Recommended Dietary Allowance (RDA). The RDA for
vitamin B12 is 2.4 µg/day, but 4-7 µg/day may be recommended based on existing vitamin body
stores and other co-morbidities.23
Individuals may also be instructed to consume varying forms of crystalline vitamin B12.
Consuming this form of vitamin B12 increases the bioavailability because it is not food-bound
and therefore does not require gastric acid for digestion and absorption. For example, individuals
ages 51 years and older are encouraged to consume fortified foods or supplements of vitamin B12
because age-related gastric changes may impair the absorption of food-bound vitamin B12 in
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8,23

older adults.

Dietary intake of vitamin B12 is usually adequate or in excess of needs in the

U.S., especially for those consuming animal sources such as meat. Since intake is usually
adequate, deficiency is much more likely to occur due to malabsorption.4

Functions and Biochemistry

Enzymatic reactions rely on adequate exogenous intake of vitamin B12 in humans. There
are two active coenzyme forms of vitamin B12, methylcobalamin and adenosylcobalamin.8 The
conversion of homocysteine to methionine via re-methylation and catalysis by methionine
synthase requires methylcobalamin.8,23 Initially, vitamin B12 bound to methionine synthase
acquires a methyl group from 5-methyl tetrahydrofolate (THF), whereas the 5-methyl-THF is the
methyl group donor and vitamin B12 acts as an intermediate acceptor of the methyl group.8,23 The
next step involves methionine synthase releasing the methyl group from the bound
methylcobalamin to be transferred to homocysteine, resulting in the products methionine and
vitamin B12.23 A deficiency of vitamin B12 halts methionine synthesis and homocysteine
accumulates, which may have adverse effects on cardiovascular health.8 This two-step reaction
makes other folate reactions occur due to the production of THF.8 In the presence of a vitamin
B12 deficiency, the methyl form of THF accumulates and becomes inaccessible via the methylfolate trap.8,23 The methionine produced is also further activated to S-adenosylmethionine
(SAM), and with a vitamin B12 deficiency, there is a decreased conversion of methionine to
SAM.23 SAM is essential for methylation reactions, which are required for myelin maintenance.
Myelin is an insulating layer, or sheath, that forms around the nerves and is responsible for
transmitting electrical impulses in nerve cells.24 If myelin is not maintained, neural function may
become compromised, resulting in neuropathy or other neurodegenerative disorders.13,23 This
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explains the neurological symptoms that accompany a vitamin B12 deficiency. Figure 1 depicts
the re-methylation of homocysteine to form methionine and the role of vitamin B12 in this
reaction.23

Figure 1:

Conversion of homocysteine to methionine

The enzyme methylmalonyl-CoA mutase requires the coenzyme adenosylcobalamin in
the form of 5-deoxyadenosylcobalamin for the reaction converting L-methylmalonyl-CoA to
succinyl-CoA.9,23 This allows succinyl-CoA to be formed and proceed to enter the citric acid
cycle, which helps to produce energy from proteins and lipids.9,23 Succinyl CoA is also required
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9,23

for the formation of hemoglobin in the red blood cells.

Two units of adenosylcobalamin are

required for this reaction, and with a vitamin B12 deficiency, the mutase activity will be impaired
and MMA will accumulate in the body fluids such as the serum and urine. uMMA can be used to
evaluate vitamin B12 tissue depletion and cellular vitamin B12 depletion.8,11,23 Figure 2 shows the
formation of succinyl-CoA and the role of vitamin B12 in this reaction.23

Figure 2:

Formation of succinyl-CoA
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Absorption, Metabolism and Storage

Vitamin B12 absorption begins in the stomach where food-bound vitamin B12 is released
from proteins by gastric hydrochloric acid (HCl-) and the gastric proteolytic enzyme,
pepsin.8,13,23,25 After the release of vitamin B12, the free vitamin B12 is bound to an R protein
(haptocorrin or transcobalamin I) from saliva and is then transported to the duodenum.8,23 This R
protein is thought to provide protection to vitamin B12 from use by intestinal bacteria.23
Next, the vitamin B12/R protein complex is acted upon by pancreatic proteases, thereby
releasing vitamin B12 from the R protein. Intrinsic factor (IF), a glycoprotein produced by gastric
parietal cells, will only bind to free vitamin B12 in a neutral environment made so by the
pancreatic proteases.23,25 IF is specific for vitamin B12 and also protects vitamin B12 from use by
intestinal bacteria.8 The vitamin B12/IF is carried from the proximal small intestine to the
terminal ileum where it is taken up by the protein receptor, cubilin.8,13,23 The proteins amnionless
and megalin associate with the vitamin B12/IF complex and facilitate the attachment of cubilin to
the ileal cell plasma membrane.8,13,23 This interaction of the vitamin B12/IF complex and cubilin
initiates a Ca2+-dependent receptor-mediated endocytosis which leads to internalization of the
complex.8,13,23 Within the enterocyte, vitamin B12 is released from IF due to the low pH within
the endosomes and lysosomes and then proceeds to bind with transcobalamin II for transport into
the portal blood.8,23 Absorption of vitamin B12 occurs primarily in the distal ileum, and while
passive diffusion may occur at very high concentrations, it is an inefficient process.13,23
Vitamin B12 is stored primarily in the liver as adenosylcobalamin in the amount of
approximately 2-4 mg.23,25 Vitamin B12 is also enterohepatically recycled, thus making it
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available for binding with IF and absorption in order to maintain the body’s need for vitamin
B12.25 This enterohepatic circulation contributes to the long biological half-life of vitamin B12. A
deficiency of vitamin B12 due to insufficient intake would take a long length of time to develop,
approximately 3-5 years.23,25 The length of time for the development of vitamin B12 deficiency
could change if there is an underlying condition or disease state such as lack of gastric acid or
pernicious anemia, in which IF is lacking.25

At-Risk Populations for Deficiency

Vegetarians and vegans are at the greatest risk of vitamin B12 deficiency due to the lack
of animal product consumption. Individuals with gastrointestinal diseases such as ZollingerEllison syndrome or Crohn’s disease are also at a higher risk of deficiency due to
malabsorption.13 Certain medications may increase the risk of developing vitamin B12 deficiency,
such as PPIs and metformin, which is used to help control blood sugar in people with Type II
diabetes.13 Older adults comprise a significant proportion of the U.S. population and are at an
especially increased risk of developing a vitamin B12 deficiency. The older adult population
experience a greater risk due to gastric changes associated with aging, such as chronic atrophic
gastritis.8 Older adults are commonly prescribed medications such as PPIs and metformin,
thereby making the risk of vitamin B12 malabsorption even greater. In studies regarding older
patients with vitamin B12 deficiency, Grober et al. state that 53% of cases were due to
malabsorption while 33% were due to anemia and only 2% due to a lack of dietary intake.13 A
Dutch study examined 105 healthy, free-living elderly persons and concluded that ≥23.8% of the
population had a mild vitamin B12 deficiency.26 Vitamin B12 deficiency was explained by low
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exogenous intake or severe atrophic gastritis in only 28% of the deficient population, leaving the
remaining cases of vitamin B12 deficiency unexplained.26
Causes of Deficiency

Malabsorption is considered to be the most common cause of vitamin B12 deficiency,
especially in the elderly.4,8 Malabsorption may be caused by many reasons, including chronic
atrophic gastritis, gastrointestinal diseases or certain drugs and medications.4,8,13,23 Two types of
chronic atrophic gastritis exist, Type A and Type B, with Type B being the most common.8 Type
A atrophic gastritis ultimately results in a lack of IF due to an autoimmune response that destroys
parietal cells and develops into megaloblastic or pernicious anemia.5,8,27 Type A chronic atrophic
gastritis is uncommon in the general population and predominates in the elderly population; it is
still relatively rare in the elderly.27 The prevalence of Type A chronic atrophic gastritis is
approximately 5% of the U.S. population.5 This condition is characterized by atrophy of the body
of the stomach while sparing the antrum.8,27 This results in achlorhydria or hypochlorhydria and
the destruction of parietal cells due to an autoimmune response producing antibodies to gastric
parietal cells leading to a loss of IF.8,27 Type A atrophic gastritis ultimately may develop into
pernicious anemia, which results from the lack of IF.
Type B atrophic gastritis is characterized by a decrease in gastric acid secretion, and
studies suggest 20-50% of the elderly are subject to this type of gastritis.8 Type B chronic
atrophic gastritis is characterized by reduced gastric acid secretions and reduced pepsinogen, and
IF may become reduced in very severe, advanced stages.5,8 Type B gastritis is thought to develop
as an end result due to a chronic infection of H. pylori.5 H. pylori decreases the gastric acidity in
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the antrum of the stomach and this decrease in acidity allows the infection to spread to the body
of the stomach, increasing bacterial colonization and hastening the progression of gastritis.4,5
Gastrointestinal diseases such as Zollinger-Ellison’s syndrome, Crohn’s disease, and
ulcerative colitis may result in malabsorption of nutrients including vitamin B12.13 ZollingerEllison’s syndrome is characterized by an increased release of gastric acid resulting in a more
acidic environment in the small intestine and therefore not allowing vitamin B12 to unbind from
the R protein and onto IF and ultimately causing the vitamin B12 to be unavailable for
absorption.23
Bacterial overgrowth caused by an increased pH of the stomach and further alkalization
of the small intestine due to achlorhydria may also contribute to vitamin B12 deficiency because
competition for the uptake of vitamin B12 may occur.8,13 Common bacterial overgrowth often
includes Campylobacter, Yersinia, and Clostridium.8 H. pylori infection may also have a
negative effect on vitamin B12 absorption by contributing to the development of chronic atrophic
gastritis.8,25 The destruction of parietal cells via the H. pylori infection and therefore the
reduction of gastric acid secretions may increase the pH of the stomach and decrease the
bioavailability of protein bound vitamin B12.25 This is especially seen in the elderly with
approximately 60% of the elderly > 60 years old being infected with H. pylori.8 One study
observed a normalization of vitamin B12 levels after treatment with antibiotic therapy, suggesting
that bacterial overgrowth may have contributed to the vitamin B12 deficiency.5
Certain medications may contribute to a vitamin B12 deficiency by promoting gastric
changes.8 PPIs inhibit gastric acid secretion and may contribute to food-bound vitamin B12
malabsorption.8 PPIs will be discussed in greater depth in the next section. Histamine2 receptor
antagonists (H2RA) such as cimetidine, famotidine, and ranitidine are used to treat peptic ulcer
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disease and may affect the absorption of vitamin B12; however, it is unclear whether these drugs
may cause an overt deficiency.9 The drug metformin may also contribute to vitamin B12
deficiency. This drug may inhibit vitamin B12 absorption by binding free calcium required for
absorption of the vitamin B12/IF complex in the terminal ileum, although research is still needed
to determine the severity of this effect.9 Other drugs known to affect vitamin B12 status include
cholestyramine, a bile acid-binding resin used to treat high cholesterol, and the antibiotics
chloramphenicol and neomycin.8 An anesthetic, nitrous oxide, may produce clinical vitamin B12
deficiency symptoms because it oxidizes and disables vitamin B12 and therefore its related
enzyme activity.9,13,23 The use of nitrous oxide should be used cautiously in individuals with a
higher risk of pre-existing vitamin B12 deficiency.9 It is also important to be observant of folic
acid supplementation because this may mask a vitamin B12 deficiency and lead to possible
irreversible neurological damages.9
Although malabsorption is the primary cause of vitamin B12 deficiency, inadequate
dietary intake may also lead to a vitamin B12 deficiency. Dietary intake of vitamin B12 has been
shown to exceed the RDA in the U.S., but people following a vegetarian or vegan diet may be at
the highest risk for deficiency. Vitamin B12 is mostly found in animal products and therefore may
contribute to a vitamin B12 deficiency if these foods are avoided and a supplement is not
untilized.8 Insufficient dietary intake may be a concern in the elderly population, but it is not the
usual cause of deficiency. Wolters et al. found the mean intake of vitamin B12 in 174 women 6070 years old to be 5.1 µg/day, clearly exceeding the RDA.8 Even in the presence of inadequate
intake, a deficiency may take 3-5 years to develop because vitamin B12 is stored long term in the
liver and is secreted in bile for reabsorption to attenuate for the lack of intake.8,23
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Signs and Symptoms of Deficiency

Overt vitamin B12 deficiency is less common and almost all cases involve mild
biochemical changes without the classic clinical manifestations such as anemia.28 Vitamin B12
deficiency progresses in four main stages. The first stage is characterized by low serum levels of
vitamin B12 on transcobalamin II, although it is important to note that serum levels may remain
relatively normal until storage is completely exhausted.8,23 The next stage involves the depletion
of cellular vitamin B12 shown by low levels of transcobalamin II, holohaptocorrin, erythrocyte
vitamin B12 concentrations, and dysfunction of vitamin B12-dependent enzymes.8,23 The third
stage results in a biochemical deficiency with a decrease in deoxyribonucleic acid (DNA)
synthesis and an increase in plasma homocysteine and MMA.8,23 The final stage manifests as a
clinical deficiency wherein blood cells are changed functionally and morphologically, resulting
in megaloblastic macrocytic anemia and neuropsychiatric disorders.8,23
The consequences of vitamin B12 deficiency are both hematological and neurological.
The Institute of Medicine (IOM) reports that 75-90% of people with clinical vitamin B12
deficiency present with neurological disorders, and this is the only expression of deficiency in
25% of cases.13 The hematological symptoms include anemia, low blood leukocyte and
thrombocyte counts, paleness of the skin, fatigue, shortness of breath and palpitations.23
Megaloblastic macrocytic anemia occurs in the final stage of deficiency due to the methyl folate
trap that occurs as a consequence of vitamin B12 deficiency.23 Without vitamin B12, the folate
coenzymes are reduced to the 5-methyl THF form and cannot be converted to the active
coenzyme form for DNA synthesis.23 This negatively affects rapidly producing cells such as the
red blood cells, thus resulting in anemia.23
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The neurological symptoms of deficiency may be irreversible if not addressed in a timely
manner.13,23 A vitamin B12 deficiency causes demyelination resulting in neurological symptoms
that include numbness in the extremities, unsteady gait, and lack of coordination and spacial
perception.13,23 Other symptoms of cerebral disorders also may be seen including confusion,
apathy, memory loss, depression, dementia, psychosis, disorientation and irritability.13,23 The
neurological symptoms are seen in approximately 75-90% of deficiency cases and are not
responsive to treatment with folate supplementation.23 Interestingly, there appears to be an
inverse relationship between severity of hematological and neurological symptoms with vitamin
B12 deficiency.13 Grober et al. argue that the neurological symptoms of deficiency are currently
largely ignored and unrecognized in clinical practice.13
As previously mentioned, homocysteine levels will rise in the presence of a vitamin B12
deficiency and this may result in cardiovascular complications such as atherosclerotic disease,
coronary artery disease, stroke, and thrombosis.5,29 The Framingham Heart Study cohort
concluded that serum vitamin B12 levels below 296 pmol/L are associated with an increase in
homocysteine levels.5 The Rotterdam Scan Study evaluated a 60-90 years old population and
found that total homocysteine levels were directly associated with silent brain infarcts and whitematter lesions.29 Seshadri et al. also evaluated the Framingham Heart Study cohort and
determined that increased plasma homocysteine seemed to be a strong independent risk factor for
the development of dementia.30 The relative risk of developing dementia was 1.4 for each
increase in 1 standard deviation above the mean and the relative risk of Alzheimer’s disease was
1.8.30 Plasma homocysteine levels above 12 µmol/L nearly doubled the risk of Alzheimer’s
disease.30 Clinical trial data have shown that brain atrophy and cognitive decline slows with
supplementation of folic acid, vitamin B12, and vitamin B6 and this may be related to the B-
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vitamin’s previously mentioned ability to allow for re-methylation or transformation of
homocysteine.28 Increased levels of homocysteine seem to have not only detrimental effects
regarding cardiovascular disease, but cognitive disorders as well.

Biomarkers

There are several biomarkers that may be used to evaluate vitamin B12 levels in the body.
The most common biomarkers include serum vitamin B12 levels, red blood cell mean corpuscular
volume (MCV), holotranscobalamin (holoTC) and serum and urinary methylmalonic acid
(sMMA, uMMA), respectively.
Serum vitamin B12 levels are assessed in the laboratory utilizing either radioimmunoassay
or chemiluminescense, meaning that normal ranges will be different depending on the assay
method used.10 Chatthanawaree states that serum vitamin B12 may not be a good indicator of
vitamin B12 deficiency or tissue depletion due to its variability.10 Generally speaking, borderline
levels are 200-300 pg/mL and vitamin B12 deficiency can be indicated by levels <200
pg/mL.8,10,13 Wolters et al. state that this level may be maintained even once the tissue stores of
vitamin B12 are exhausted.8 Thus, serum vitamin B12 levels <300 pg/mL, and <350 pg/mL for the
elderly, should be verified with other tests.8 It is also important to note that a functional vitamin
B12 deficiency may be present with serum levels up to 450 ng/L.13 The lack of serum sensitivity
for vitamin B12 suggests that metabolite testing be used in conjunction with serum measurements
when diagnosing a vitamin B12 deficiency.10
MCV can be utilized because a methylcobalamin deficiency causes a build-up of the
inactive form of folate (5-methyltetrahydrofolate) and a decreased level of active folate
(tetrahydrofolate) in the body.10 This biomarker is not specific to vitamin B12 or folate. Levels
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greater than 130 fL are 100% indicative of a deficiency of either vitamin B12 or folate, but an
elevation in MCV is a relatively late sign of a deficiency and not a good indicator for a vitamin
B12 deficiency diagnosis.8,10
Holotranscobalamin is a biomarker that becomes reduced with a vitamin B12 deficiency.
This is the active part of the vitamin B12 that delivers the vitamin to the body cells and is thought
to be the earliest marker for a vitamin B12 deficiency, but limitations include its short half-life in
the plasma and poor specificity.10,13 A level of <35-45 pmol/L is used to indicate deficiency of
vitamin B12.10,13
MMA is the hallmark of vitamin B12 deficiency and a highly sensitive functional
indicator that indicates tissue depletion.8,10,11,13 If a vitamin B12 deficiency is present, a lack of
adenosylcobalamin will be present and this will cause an accumulation of D-methylmalonylCoA, which is then converted to MMA. MMA can be measured in both the serum and urine.10
This test may be costly due to the equipment needed such as a mass spectrometer to analyze the
serum or urine, but this metabolic byproduct can be used to detect tissue levels of vitamin B12
before serum vitamin B12 measures would indicate such a deficiency.8,10,13 Normal levels for
sMMA are 70-270 nmol/L.10 Lukaszuk et al. used uMMA in their analysis of vitamin B12 levels
in non-elderly individuals and defined normal levels of uMMA <3.8 µg MMA/mg creatinine
(<3.6 µmol/mol creatinine).12,31
One study screened for low uMMA at various health fairs, retirement communities and
other locations geared towards the elderly population. uMMA was taken from 809 individuals
and 36 participants had elevated uMMA, defined as > 5.0 µg MMA/mg creatinine.32 Of these 36
participants, only 18 subjects had low serum vitamin B12 while 17 subjects had low-normal or
normal vitamin B12 levels.32 Twenty-three subjects then received intramuscular vitamin B12 and
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16 subjects were seen after the treatment. All these participants now had a statistically significant
decrease in uMMA levels showing that uMMA responds to changes in vitamin B12 levels and
that this biomarker is more sensitive in detecting a vitamin B12 deficiency.32 Another study
analyzing the dose response of vitamin B12 supplementation of uMMA levels recruited
individuals with poor vitamin status defined as plasma vitamin B12 <250 pmol/L and uMMA
ratio >1.5 µmol MMA/mmol creatinine.11 Hill et al. observed that with supplementation of
vitamin B12, uMMA levels decrease rapidly within the first 2 weeks of supplementation with no
further decrease thereafter, suggesting that correcting the metabolic effects of poor vitamin B12
status can be done fairly quickly, especially with a high supplemental dose.11
Although the sMMA and uMMA respond similarly to supplementation, the uMMA is
superior to that of sMMA due to its increased sensitivity for vitamin B12 status.11 sMMA may be
falsely elevated due to renal insufficiency while uMMA does not show much variation; however,
creatinine should be utilized when interpreting uMMA to account for possible kidney function
impairment.13,31 uMMA is also 40 times more concentrated than sMMA and the test is noninvasive and only requires 1 mL of urine, which may be frozen for months.14,31 False positives
have not been reported with uMMA.14 Both the serum and urinary MMA biomarkers have a
higher sensitivity and specificity than serum vitamin B12.10 A potential drawback is the need for
implementation of a quality assurance system regarding the uMMA measurements. Researchers
from the Hospital of the University of Munich, Germany, found a deviation of >20% from the
mean concentration of uMMA samples in a large proportion of samples submitted by ten
European clinical laboratories.33 This may not have implications for research in the U.S., though,
and one can easily control for this variable by having all samples evaluated by one lab.
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Prevalence of Deficiency in the Aging Population

Vitamin B12 deficiency or suboptimal levels in the elderly are relatively common, but
little research focuses on vitamin B12 deficiency in the 50-70 years old population. Although
vitamin B12 deficiency is common in the aging population, deficiency is not seen as a direct
consequence of aging. The mechanism producing vitamin B12 deficiency in the elderly seems to
be due to an increased susceptibility due to accompanying disease states or use of medications
that contribute to malabsorption.27
Diagnosis of vitamin B12 deficiency varies greatly due to differing criteria for defining
deficiency, but deficiency is more prevalent with older age and among Caucasians and Latinos.10
When evaluating studies from 2005-2007, Chatthanawaree states the reported prevalence varies
from 0.6 to 46%.10 Desirable status for the elderly using serum vitamin B12 is 220-258 pmol/L
(300-350 pg/mL), and when used in conjunction with more sensitive biomarkers such as
homocysteine and MMA, the prevalence of vitamin B12 deficiency in the elderly is roughly
43%.8 Vitamin B12 status was observed in the Framingham Heart Study cohort elderly population
aged 67-96 years old using both serum vitamin B12 and metabolic markers such as sMMA and
homocysteine; 40.5% had serum vitamin B12 concentrations <258 pmol/L, and sMMA and
homocysteine concentrations were markedly elevated along with low vitamin B12 levels in
11.3% of the elderly participants.34 This indicates that greater than 12% of this particular
ambulatory, elderly population had vitamin B12 deficiency and many of these individuals had
normal serum vitamin B12 levels, indicating the need to test metabolic markers and not solely
serum levels of vitamin B12.34 Various studies from around the world have found vitamin B12
deficiency to occur in between 7% to 30% in the elderly population in various settings including

13,26,35-37

free-living, assisted-living and skilled care.
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It is also important to note that intake may be

adequate, but a deficiency may still exist due to the many functional factors that may inhibit
absorption and contribute to the development of a vitamin B12 deficiency.13 The research shows
that vitamin B12 deficiency seems to increase with age, thus contributing to the importance of
identifying a deficiency earlier in the 50-70 years old population to address any low levels prior
to progression of deficiency.

Proton Pump Inhibitors

PPIs are pharmacological agents with gastric-acid-suppressing characteristics. Examples
of PPIs include omeprazole, lansoprazole, rabeprazole, pantroprazole and esomeprazole.4 PPIs
have shown to be far superior to H2RA because they are more potent suppressors of gastric
acid.38 PPIs were introduced in the mid to late 1980’s and are generally viewed as safe and
effective.3,25 However, consequences of long-term use are not completely understood and
potential long-term consequences such as vitamin B12 malabsorption are of great concern in
vulnerable populations such as the elderly.25

Indications and Uses

PPIs are clinically indicated for use in GERD, esophagitis, acid hypersecretory states
such as Zollinger-Ellison syndrome, peptic ulcers, H. pylori infection, dyspepsia and prophylaxis
of peptic ulcers.22,25,38 These drugs are often recommended as a first line of therapy for more
serious conditions such as erosive esophagitis and Barrett’s esophagus.4,38 PPI use is also
indicated in individuals taking other medications such as non-steroidal anti-inflammatory drugs
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(NSAIDs), low-dose aspirin (up to 325 mg/day), corticosteroids, antiplatelet drugs and
anticoagulants, which may increase risk of upper GI bleeding.4,22,25,38
There is concern regarding the potential overutilization of PPI therapy. Inappropriate
prescription of PPI is defined by lack of medical indication, inappropriate duration of treatment,
and inappropriate dose.4 Inappropriate PPI use is not uncommon and some studies report that
inappropriate use is seen in approximately 50-80% of elderly patients admitted and discharged
from geriatric wards.4 Elderly patients often remain on PPIs after H. pylori infection is totally
eradicated. It is reported that 50-60% of PPI users for treatment of H. pylori infection became
chronic PPI users.4 This indicates many individuals, especially the elderly, may needlessly
become chronic PPI users, thereby increasing their risk of nutrient malabsorption.39 PPIs are also
available over-the-counter without a prescription and this allows individuals to self-prescribe,
leading to improper use in many cases.39

Mechanism of Action

PPIs suppress gastric acid output via selective inhibition of the hydrogen potassium
ATPase pump.40 PPIs require activation by parietal cells in the presence of gastric acid leading to
formation of a sulfonamide moiety which then irreversibly binds to the alpha subunit of the
hydrogen potassium ATPase pump on the secretory canaliculus of actively secreting parietal
cells, thus inhibiting the ability of parietal cells to produce hydrochloric acid.3,40 The reduced
gastric acid output of the parietal cells leads to increased gastric pH that causes the inhibition of
somatostatin release from D-cells in the gastric antrum.3 The lack of somatostatin release allows
gastrin to be released from G-cells completely unrestrained. This leads to increased serum levels

22
3

of gastrin. PPIs are metabolized primarily by the cytochrome P450 enzymes in the liver and
then excreted predominantly via the urine.3

Potential Side Effects

Common side effects of PPI use include headache, diarrhea, constipation, nausea and
rash, but these are rather infrequent and mild.4 Other less overt side effects exist regarding
absorption of nutrients with long-term use and may have a larger impact on overall health.

Nutritional Deficiencies - Vitamin B12

There are different mechanisms that may be working to affect vitamin B12 absorption. A
lack of gastric acid can inhibit the release of dietary vitamin B12 from food because gastric
acidity is required to activate pepsinogen to pepsin which is required to liberate protein-bound
vitamin B12 from food sources, thus decreasing the bioavailability of vitamin B12.4,8,13,22,25,41
Gastric acid itself also helps to free vitamin B12 from food, and if this is suppressed, absorption
may be affected. Furthermore, gastric and small intestinal bacterial overgrowth may occur due to
the increased pH in the stomach and the small intestine and these displaced bacteria can compete
with the gut for absorption and use of vitamin B12. A recent review concluded that gastric
bacterial overgrowth has not been shown to have nutritional consequences, although uncertainty
regarding this conclusion still exits.4,8 Another suggested mechanism is the destruction of
parietal cells, which produce IF, leading to the development of pernicious anemia by the inability
of IF to bind vitamin B12 and become absorbed.25 However, pernicious anemia is relatively
uncommon and decreased IF has not been seen with PPI use.25
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Rebound Acid Hypersecretion

Rebound acid hypersecretion refers to the increase in gastric acid secretion after PPI
treatment has been discontinued.22 PPI therapy causes a decrease in gastric acid secretion and
release of somatostatin by antral D-cells which then continues to an increased amount of gastrin
released from G-cells.3,22 Hypergastrinemia ensues and this increases the functional capacity of
enterochromaffin-like cells and parietal cells, thereby leading to increased gastric acid
secretion.22 Sustained hypergastrinemia can increase acid secretion, but it does not become
evident until cessation of PPI therapy, when symptoms reoccur with increased severity. This
increased severity of gastric acid secretion often leads to chronic PPI therapy.22,41

Relationship Between PPI Use and Vitamin B12

The current body of research regarding vitamin B12 deficiency and use of acid-lowering
medications such as PPIs and H2RAs is conflicting and results are varied. Lukaszuk et al.
compared vitamin B12 status in non-elderly (22-50 years old) chronic PPI users (daily use of PPIs
for at least 1 year) who were age- and gender-matched with non-PPI users serving as the control
group.12 No significant differences were found between uMMA in PPI users and their matched
controls.12 This study was unique because it was the first to examine uMMA levels in nonelderly individuals; however, this study was limited by a small sample size.12 A 2010 study
analyzed institutionalized individuals between 60-89 years old regarding vitamin B12 status in
PPI users (n=17) and non-PPI users (n=19). Groups were not age- and gender-matched as in the
previous study, but PPI usage was characterized as continuous use of PPIs for at least 1 year.17
At baseline, there was a significant difference in the frequency of vitamin B12 deficiency in PPI
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users and non-PPI users, with 11 of 16 deficient in the PPI group and 2 of 18 deficient in the
non-PPI group.17 The entire PPI group were then supplemented with a nasal vitamin B12 spray of
500 µg once per week for eight weeks. Pre- and post-serum vitamin B12 levels and sMMA were
collected. At conclusion of the study, the vitamin B12 nasal spray increased serum vitamin B12
levels in the PPI users and decreased the number of vitamin B12-deficient institutionalized
individuals.17 The frequency of deficiency from baseline to 8 weeks was significant with 10 of
13 PPI users being deficient at baseline.17 Only five PPI users remained deficient after 8 weeks
of treatment with vitamin B12 nasal spray.17 This study was also limited by a small sample size,
similar to Luksaszuk et al., and neither a food record nor food frequency was obtained in the
study. There was also no placebo control group regarding the supplementation with nasal vitamin
B12 spray because it is not ethical to withhold treatment from individuals with a known vitamin
B12 deficiency.17
Three studies were published in 2008 and their conclusions varied. A cross-sectional
study by Den Elzen et al. aimed to investigate the suspected association between long-term PPI
use and abnormal vitamin B12 status in elderly individuals.16 Long-term PPI use was
characterized by >270 defined daily doses per year for 3 years and elderly was characterized by
ages ≥65 years old. The PPI user must have had a partner such as a husband, wife or child that
met the inclusion criteria and had not used a PPI within the last 3 years or received parenteral
vitamin B12 treatment. These partners were not age- and gender-matched as with the previous
studies mentioned. The purpose of these pairs was to control for dietary intake of vitamin B12.
One hundred twenty-five couples were identified that qualified to participate in this study. Blood
sampling was performed to test serum levels of vitamin B12, serum levels of homocysteine and
MCV. Overall, no association was found between long-term PPI use and poor vitamin B12 status
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in elderly individuals in this study. This study was not limited by a small sample size or short
duration of PPI use, as users had been on PPIs for at least 3 years, but the authors suggest that a
“healthy user” effect may have been at play due to the exclusion criteria.16 Another issue could
have been the lack of matching for age and gender and the biomarkers used to measure vitamin
B12 status because serum vitamin B12, homocysteine and MCV are not sensitive or specific
indicators of vitamin B12 status. This study was also conducted in a community-living older adult
population which may differ from institutionalized older adults.
Two other 2008 studies indicated that prolonged PPI use did indeed negatively affect
serum vitamin B12 levels. The cross-sectional study by Dharmarajan et al. aimed to examine the
relationship between serum vitamin B12 levels and use of PPIs and H2RA in older adults ages 60102 years old over a duration of 6 years.18 The sample of participants was taken from a long-term
care facility and a community health center in the Bronx, New York. Five hundred forty-two
patients were eligible to be included in the data and information was collected about
demographics, PPI or H2RA use, and vitamin and mineral supplement use.18 The results
indicated that low or marginal vitamin B12 status was observed in older adults with 19.9% in the
nursing-home population and 29.2% in the community-living population.18 The results showed
that PPI use up to 72 months was associated with lower serum vitamin B12 levels for both
supplement and non-supplement users.18 This decrease in serum vitamin B12 levels was not seen
with the use of H2RA.18 Vitamin B12 supplements of 7-50 µg/day did not prevent lower vitamin
B12 levels, but it did delay the occurrence of vitamin B12 deficiency.18 Food records to analyze
dietary intake were not collected, which may have been a limitation. The authors concluded that
deficiency is indeed common among the older adult population, but special attention may be
necessary to monitor vitamin B12 levels in older adults utilizing PPIs.18

26
A study by Hirschowitz et al. followed up a prior study following acid hypersecretors
with or without Zollinger-Ellison syndrome. In the prior study, subjects were treated with
lansoprazole and results showed this PPI effectively decreased gastric acid secretion.15 The
follow-up study aimed to determine prevalence of vitamin B12 deficiency in very long-term PPI
users measuring serum vitamin B12, sMMA, and homocysteine. This is significant because prior
to this study, the sMMA and homocysteine tests had not been utilized in previous studies of
vitamin B12 malabsorption in omeprazole-treated patients. One finding was that the patients with
altered homocysteine or sMMA levels showed a normalization of these levels when
supplemented with vitamin B12.15 Utilizing these additional tests (MMA and homocysteine),
subclinical vitamin B12 deficiency was discovered in 31% of patients with normal serum vitamin
B12 levels.15 Hirschowitz et al. did not find that prolonged or excessive acid or pepsin
suppression was the explanation for the vitamin B12 deficiency observed, indicating that another
mechanism may be responsible, which continues to remain unknown. Hirschowitz et al. did not
focus on elderly individuals, but subjects were utilizing PPIs long term and the average age was
between 52.9-56.3 years.15
A 2004 case-control study investigated the association between vitamin B12 deficiency
and use of H2RA and PPIs in older adults ≥ 65 years old.19 Inclusion criteria included a
documented serum vitamin B12 measurement. This information was obtained via a universitybased, geriatric, primary-care facility’s medical records.19 Fifty-three people met criteria for the
vitamin B12 deficient group and a set of controls were matched within one year of age and sex, in
a ratio of 4:1, with 212 people constituting the normal-status control group.19 Overall, chronic,
defined as greater than 12 months, and current use of H2RA and/or PPI was associated with
significantly increased risk of vitamin B12 deficiency.19 It was also found that multivitamin use
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did not protect against deficiency of vitamin B12. Dharmarajan et al. found similar results and
19

both Valuck and Ruscin and Dharmarajan et al. recommend screening of elderly individuals to
reduce any complications that may arise due to untreated vitamin B12 deficiency.18,19 Valuck and
Ruscin did not differentiate between H2RA use and PPI use and recent studies have indicated
that H2RAs do not have an effect on vitamin B12 levels.19
A 2002 case study followed a 78-year-old woman using H2RAs and PPIs long term (4.5
years) for treatment of GERD.42 Serum levels of vitamin B12 were adequate at baseline and the
patient developed a vitamin B12 deficiency after prolonged use of both H2RA and PPIs, although
the vitamin B12 deficiency was not shown until after use of PPIs.42 When supplemented with
1000 µg/day, vitamin B12 status improved, although sMMA and homocysteine did remain
slightly elevated in the patient.42 This improvement of vitamin B12 levels indicates that
malabsorption of food-bound B12 occurred, not lack of IF.42 Overall, Ruscin et al. concluded that
vitamin B12 deficiency should be considered in long-term use of PPIs, especially in people with
poor nutritional intake.
Two 1994 studies analyzed vitamin B12 absorption with omeprazole or hypochlorhydric
states.21,43 These studies both examined short-term use of omeprazole. Marcuard et al. provided
either 20 mg or 40 mg of omeprazole daily for two weeks to participants and Saltzman et al.
provided 40 mg of omeprazole daily for a minimum of 7 days.21,43 Both studies found that
omeprazole treatment did in fact impair protein-bound vitamin B12 absorption, but Saltzman et al.
observed that the Schilling tests using crystalline vitamin B12 were normal among all groups (i.e.
control group, omeprazole treatment, and atrophic gastritis group).21 A Schilling test is used to
identify if vitamin B12 is absorbed normally.21,43 Marcuard et al. stated that omeprazole therapy
causes a dose-dependent decrease in absorption of vitamin B12.43 Saltzman et al. concluded that

28
21

this impairment was similar to what occurs in atrophic gastritis. Both studies are limited by
small sample size with 10 participants and 19 participants, respectively. The age groups
examined also differed, with Marcuard et al. examining 10 healthy male volunteers 22-50 years
old while Saltzman et al. examined healthy, free-living elderly individuals >60 years old.21,43
Saltzman et al. also examined if an acidic beverage ingested with protein-bound vitamin B12
would increase absorption of vitamin B12.21 It was found that cranberry juice and a diluted HClsolution did indeed increase the absorption of protein bound vitamin B12, although more research
is needed to confirm if this finding was of clinical significance.21
A 1992 study aimed to examine the effect of prolonged omeprazole therapy on
absorption of micronutrients including vitamin B12.44 The participants had been taking
omeprazole for 6-48 months primarily for GERD at a dosage of primarily 20 mg/day.44 Although
a downward trend regarding vitamin B12 status was observed after 3 years of treatment, this was
not statistically significant.44
To summarize, many studies support the hypothesis that long-term use of PPIs (at least 1
year) may be associated with low serum vitamin B12 levels although the etiology is not
completely understood. Most studies examined serum vitamin B12,with newer research utilizing
MMA and homocysteine in conjunction with serum vitamin B12 due to the increased sensitivity
of these biomarkers. No studies have investigated uMMA as a biomarker in older adult patients
utilizing PPIs.

Conclusion

The research shows that the elderly are more susceptible to vitamin B12 deficiency due to
age-related gastric changes and polypharmacy, although the population ages 50-65 are largely
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ignored in the literature. Specifically, PPIs may exacerbate the gastric effects of chronic atrophic
gastritis, which is commonly found in the aging population. Insufficient dietary intake is
typically not the cause of a deficiency while malabsorption seems to be the main culprit. The
biomarkers used to determine deficiency, such as serum vitamin B12, are not as sensitive as
uMMA and may underestimate the level of deficiency. Untreated vitamin B12 deficiency may
lead to worsened neurological symptoms which may lead to cognitive impairment and reduced
quality of life. If a deficiency is not addressed in a timely manner, the neurological effects may
be irreversible. It is worthwhile to add to the current body of research regarding the usefulness of
uMMA and the importance of identifying vitamin deficiencies in a timely manner to prevent any
deleterious effects in the aging population in order to protect this population and maintain
optimal cognitive function and quality of life as this generation begins to approach advanced age.

CHAPTER 3
METHODS

Selection of the Sample

A quasi-experimental design was used for this study. Thirty men and women between the
ages of 50-70 years old were recruited using informational flyers posted in local assisted-living
facilities, the university campus, and other community locations (Appendix A). Flyers were also
posted via social media avenues and phone calls were made to recruit participants using a
standardized recruitment script (Appendix B). A recruitment screening form was also utilized to
assist with filtering eligible and non-eligible participants (Appendix C). Approval from the
Institutional Review Board (IRB) and Institutional Biosafety Committee (IBC) of Northern
Illinois University was obtained before recruitment of participants and data collection (Appendix
D and E) and all subjects signed an informed consent prior to participating in this study
(Appendix F).
Fifteen subjects were recruited based on daily use of PPIs for a minimum of one year.
Fifteen subjects were then recruited based on no past or current use of PPIs and these participants
were age- and gender-matched to subjects in the PPI group. The participants were age-matched
within ±3 years. Exclusion criteria included history of Crohn’s disease, ulcerative colitis,
pernicious anemia, liver or kidney disease, use of metformin, adherence to a vegetarian or vegan
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diet, or use of intramuscular shots of vitamin B12 or nasal Nascobal (Strativa Pharmaceuticals,
Spring Valley, NY).

Data Collection

Data collection occurred at the nutrition laboratory in Wirtz Hall 308A at Northern
Illinois University. Appointments were scheduled for participants based on availability and
convenience of the participants. At the appointment, a consent form (Appendix F) was
administered and signed by each subject, and subjects were instructed to bring a completed
three-day food record (Appendix G). This three-day food record was mailed or hand delivered to
participants before their appointment and questions were addressed regarding the food log at that
time. A short survey was administered (Appendix H and I) and then anthropometrics were
assessed followed by collection of a urine sample for uMMA assay.

Instruments

Survey

An informational survey was administered to participants to collect information regarding
demographics, lifestyle behaviors, use of vitamin supplements and use of PPIs. Habits that were
questioned included smoking habits, use of vitamin B12, vitamin B6 and folic acid
supplementation, and use of specific PPIs (Appendix H and I). These surveys were analyzed by
the researcher and responses were compiled and entered into the Statistical Package for Social
Sciences (SPSS) for Windows (Version 21.0, 2013, SPSS, Inc, Chicago, IL).
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Diet Analyses

Nutrition Calc Plus (version 3.6.1 McGraw-Hill Companies, Columbus, OH) was utilized
to assess each participant’s three-day food record (Appendix G). Analyses performed included
the following: total Kcal/kg; fat, protein and carbohydrate as percentages of total Kcal/kg; and
dietary vitamin B12, vitamin B6 and folic acid. The diet analyses were completed by the
researcher to allow for consistency when interpreting information provided from the three-day
food records.

Anthropometrics

Participants had anthropometric measures completed in lightweight clothing and bare
feet. Height was obtained to the nearest half inch at the time of the appointment using a wallmounted stadiometer (Ayrton S-100, Prior lake, MN). Weight, fat mass, body fat percent, fat free
mass and body mass index (BMI) was assessed utilizing a bioelectrical impedance scale (InBody
520, Biospace Inc., Los Angeles, CA). BMI was calculated by the InBody 520 using the standard
equation (kilogram per meter squared).

Urine Samples

Urine samples were collected in sterile containers and transferred to vials containing 5
mg of thymol as a preservative, allowing samples to be mailed unrefrigerated. The vials were
stored at -20ºC until all data had been collected. The samples were then shipped overnight to
Norman Clinical Laboratory, Inc. (Cincinnati, Ohio) for analysis.
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Laboratory Measurements

The urine samples were analyzed by Norman Clinical Laboratories Inc. (Cincinnati,
Ohio). Urine levels of MMA were determined using an ion-monitoring isotope dilution gas
chromatography mass spectrometry (GC/MS). uMMA levels were normalized to urinary
creatinine levels. Five hundred ng of deuterated MMA as an internal standard and a gas
chromatograph (Varian 3400, Varian Associates, Sugarland, TX) equipped with a capillary
column (30-m, DB-5, 0.25-um film thickness, 0.5 mm inner diameter, J&W Scientific Co.,
Folsom, CA) were interfaced to a mass spectrometer (Finnigan MAT 800 ion trap detector, San
Jose, CA). The GC/MS was equipped with a Finnigan MAT A200S autosampler. The GC was
programmed from 140º to 225ºC at 4.7ºC/min and then to 280ºC at 20ºC/min with a 10-minute
hold time. For the data analysis, levels of uMMA are considered to be normal if they were <3.8
µg MMA/mg creatinine or <3.6 mmol/mol creatinine.12

Data Analysis

Due to the small sample size and the matched-pairs design, this study used the nonparametric related-samples Wilcoxon signed rank test to determine differences in key variables
between PPI users and non-PPI users.12,45 This test was also used to test the hypothesis that
subjects using PPIs would have higher uMMA levels than their age- and gender-matched
controls not using PPIs.12,45
The mean and standard deviation were determined for each key variable between PPI
users and non-PPI users and provided as M ± SD. The median was also provided for each key
variable. The tests for equivalency between key variables of each group was provided as a Z-
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value. The testing of the hypothesis was also reported as a Z-value. Statistical significance for all
data analysis was accepted at the p<0.05 level of confidence. Data was analyzed by using the
Statistical Package for Social Sciences (SPSS) for Windows (Version 21.0, 2013, SPSS, Inc.,
Chicago, IL).

CHAPTER 4
RESULTS

Research Methodology

The purpose of this study was to determine if uMMA increases with chronic use of PPIs.
First, PPI users were recruited and then gender-matched and age-matched (±3 years) with nonPPI users. Participants were required to provide a urine sample in order to evaluate uMMA.
Participants were also required to complete a three-day food record for nutritional analysis,
complete a survey regarding demographic and lifestyle habits, and consent to collection of
anthropometric data.

Participants

General Characteristics

The participants ranged in age from 50-68 years old with a mean age of 56.6 years old.
Participants were gender-matched and age-matched within ±3 years. Ten males and 20 females
participated in the study. The mean BMI for the PPI users was 33.2 and the mean BMI for the
non-PPI users was 28.3, which was significantly different (Z=-2.33, p=0.02). Most participants
were Caucasian (93.3%, n=28) while 6.7% of the participants were African American (n=2).
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Physical Activity

A third of participants reported no structured physical activity (33.3%, n=10) while 20%
(n=6) reported structured physical activity 5 days per week. Twelve participants reported
structured physical activity ranging from 2-4 days per week (13.3%, n=4) while 3.3% (n=1) of
participants reported structured physical activity both 1 day per week and 7 days per week. Of
those participants who exercised, 20.0% (n=6) reported length to be approximately 30-39
minutes and only 6.7% (n=2) reported exercise to last 60 minutes or longer. Most exercising
participants (40.0%, n=12) reported physical activity to be moderate intensity and 20.0% (n=6)
reported low intensity exercise.

Details Regarding PPI Use

The PPI users had been taking PPIs for a range of 1.5-15 years with a mean of 7 years
(M(SD)= 7.0±3.9, Mdn=7.0). Two participants reported taking PPIs over-the-counter (13.3%,
n=2), nine participants reported taking PPIs under doctor’s orders (60%, n=9), and the remaining
four participants reported taking PPIs over-the-counter with a doctor’s guidance (33.3%, n=4).
Acid reflux was the most common reason for PPI prescription with 86.7% (n=13) of PPI users
reporting acid reflux or GERD as the reason for PPI use. The remaining two PPI users reported
use of PPIs for a hiatal hernia and gastritis.
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Equivalency of Groups

Physical Characteristics

The PPI users and non-PPI users were tested for equivalency using the related-samples
Wilcoxon signed rank test. The PPI users and non-PPI users were significantly different
regarding BMI (Z= -2.33, p=0.02), body fat percent (Z=-2.36, p=0.02), and body fat mass
(Z= -2.33, p=0.02). PPI users, on the average, had a higher BMI, body fat percent, and body fat
mass. Despite these differences, the groups were not significantly different in age (Z= -0.11,
p=0.9) or lean body mass (Z= -0.91, p= 0.36). Table 1 provides the mean, median and
significance level of the physical characteristics of PPI users and non-PPI users and Figure 3
displays the mean for each physical characteristic for PPI users and non-PPI users.

Table 1
Physical Characteristics of PPI Users and Non-PPI Users

Age
BMI
Body Fat Percent (%)
Body Fat Mass (kg)
Lean Body Mass (kg)

PPI Users (n=15)
Mean±SD Median
56.6±5.5
56.0
33.2±6.6
30.9
40.4±8.2
39.8
38.3±14.3
33.1
54.7±10.3
53.0

Non-PPI Users (n=15)
Mean±SD
Median
56.5±5.2
54.0
28.3±4.4
27.3
35.1±8.0
35.6
28.6±9.6
26.3
52.0±10.5
51.7

Note: P values results from related-samples Wilcoxon signed rank tests.
* indicates p<0.05
SD = Standard deviation

P Value
0.91
0.02*
0.02*
0.02*
0.36
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Dietary Intake

Dietary intake data was not available for one non-PPI user participant; therefore, the data
presented for dietary intake reflects the related-samples Wilcoxon signed rank test using 14 pairs.
Dietary intake descriptive values were calculated with 29 participants and equivalency of group
regarding dietary intake was analyzed using 14 vs. 15 pairs. Most participants reported having an
excellent appetite, 63.3% (n=19), while 26.7% (n=8) reported a good appetite and 10.0% (n=3)
reported a fair appetite. Tests for equivalency of groups indicated no significant differences
between average daily caloric intake (kcal/kg) (Z=0.09, p=0.93), carbohydrates as percentage of
caloric intake (Z=0.03, p=0.98), protein as percentage of caloric intake (Z=-1.41, p=0.16), fat as
percentage of caloric intake (Z=1.73, p=0.08), dietary vitamin B12 (µg) (Z=-1.15, p=0.25), dietary
vitamin B6 (mg) (Z=-1.29, p=0.20), and dietary folate (µg) (Z=-0.66, p=0.51). Table 2 provides
the mean, median and significance level of dietary intake for PPI users and non-PPI users. Figure
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4 displays the mean for all dietary intake except dietary folate for PPI users and non-PPI users
and Figure 5 displays the mean for dietary folate intake for PPI users and non-PPI users.

Table 2
Dietary Intake of PPI Users and Non-PPI Users
PPI Users (n=15)
Mean±SD
Median
Average Daily Caloric
Intake (kcal/kg)
Carbohydrate as % of
Caloric Intake
Protein as % of Caloric
Intake
Fat as % of Caloric Intake
Dietary Vitamin B12 (µg)
Dietary Vitamin B6 (mg)
Dietary Folate (µg)

Non-PPI Users (n=15)
Mean±SD Median

19.3±6.7

18.1

20.0±4.7

20.4

0.93

40.9±6.3

39.7

41.2±5.5

40.8

0.98

20.6±4.2
36.7±4.7
3.8±3.1
1.1±0.7
262.0±195.3

19.5
36.3
2.9
0.8
185.2

18.2±3.3
38.8±4.8
2.7±1.8
1.1±0.8
178.0±105.3

18.0
38.2
2.0
0.8
173.2

0.16
0.08
0.25
0.20
0.51

Note: P values results from related-samples Wilcoxon signed rank tests. Total of percentages for
carbohydrates, protein, and fat may not equal 100% due to rounding.
SD = Standard deviation
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Supplemental Intake

Tests for equivalency of groups regarding supplemental intake indicated no significant
difference between supplemental vitamin B12 (µg) (Z= -0.23, p=0.82), supplemental vitamin B6
(mg) (Z= -0.09, p=0.93), and supplemental folic acid (µg) (Z= 0.00, p=1.00). Only six PPI users
did not consume a multivitamin while the remaining PPI users consumed a multivitamin with
vitamin B12, vitamin B6, and folic acid with one PPI user taking a super vitamin B-complex
daily. Eight non-PPI users reported not using a multivitamin while the remaining seven non-PPI
users consumed a multivitamin daily. Table 3 provides the mean, median and significance level
of supplemental B vitamin intake. Figure 6 displays the mean supplemental intake of vitamins
B12 and B6 and Figure 7 displays the mean supplemental intake of folic acid.
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Table 3
Supplemental Intake of PPI Users and Non-PPI Users
PPI Users (n=15)
Mean±SD Median
Supplemental Vitamin B12 (µg)
Supplemental Vitamin B6 (mg)
Supplemental Folic Acid (µg)

Non-PPI Users (n=15)
Mean±SD
Median P Value

25.8±35.3

15

64.1±204.1

0.0

0.82

3.0±2.8

3

3.7±6.5

0.0

0.93

246.7±216.7

400

293.3±439.9

0.0

1.00

Note: P values results from related-samples Wilcoxon signed rank tests.
SD = Standard deviation

70
60
50
40
30
20
10
0
Supplemental Vitamin B12 (µg)
PPI Users (n=15)

Figure 6:

Supplemental Vitamin B6 (mg)
Non-PPI Users (n=15)

Supplemental intake of PPI users and non-PPI users

42

300
290
280
270
260
250
240
230
220
Supplemental Folic Acid (µg)
PPI Users (n=15)

Figure 7:

Non-PPI Users (n=15)
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Urinary Methylmalonic Acid

uMMA ranged from 0.90 to 2.80 µg/mg creatinine among the PPI users and 1.20 to 3.30
µg/mg creatinine among the non-PPI users. The mean uMMA for PPI users was 1.6 µg/mg
creatinine (M(SD)= 1.6±0.6, Mdn=1.6) while the mean uMMA for the control group was 2.0
µg/mg creatinine (M(SD)=2.0±0.6, Mdn=1.8). The hypothesis that PPI users would have higher
uMMA levels than their gender-matched and age-matched controls was not supported (Z=1.54,
p=0.12). Table 4 provides the mean, median and significance level of uMMA and Figure 8
displays the mean uMMA for PPI users and non-PPI users.
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Table 4
Urinary Methylmalonic Acid Levels of PPI Users and Non-PPI Users
PPI Users (n=15)
uMMA Levels
(µg uMMA/mg creatinine)

Non-PPI Users (n=15)

Mean±SD

Median

Mean±SD

Median

P Value

1.6±0.6

1.6

2.0±0.6

1.8

0.12

Note: P values results from related-samples Wilcoxon signed rank tests.
SD = Standard deviation

2
1.5
1
0.5
0
uMMA Levels (µg uMMA/mg creatinine)
PPI Users (n=15)

Figure 8:

Non-PPI Users (n=15)
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CHAPTER 5
DISCUSSION

This study shows for the first time that there were no differences in uMMA levels
between those taking PPIs versus those not taking PPIs in the 50-70-year-old age range. The
findings of this study concur with those of Lukaszuk et al., who evaluated uMMA levels in 2250-year-old adults.12 Two additional studies conducted among adults in their mid-fifties and
those who were >65 years old also found that taking PPIs did not deleteriously affect serum
vitamin B12 levels.15,16 In direct contrast to the findings of these studies, three other studies found
that PPI use of at least one year negatively affected serum vitamin B12 status; however, the
average age of the subjects in those studies was 80-82 years old, much older than the average age
of the subjects in this study, which was 57 years old.17-19
Ruscin et al. recommended monitoring of vitamin B12 status in individuals taking PPIs for
more than four years because PPIs may reduce vitamin B12 absorption.42 In this current study, 10
of 15 subjects had been taking PPIs for more than 5 years and 7 of 15 subjects had been taking
PPIs for more than 7 years, yet their uMMA levels remained within a normal range. The study
results seem to indicate that PPI users recruited for this study had GERD but were otherwise
healthy and likely had normal vitamin B12 stores before being placed on PPIs. Thus, monitoring
may still be recommended for those at higher risk of vitamin B12 deficiency.

23,25

Vitamin B12 is stored and endogenously recycled via the liver.
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As stated previously, a

deficiency of vitamin B12 would take a long length of time to develop, approximately 3-5
years.23,25 The PPI users in this study had been taking PPIs for an average of 7 years, yet their
uMMA levels indicated that tissue stores of vitamin B12 remained within a normal range.

Physical Characteristics

PPI users and non-PPI users were significantly different regarding BMI, body fat percent,
and body fat mass, with PPI users displaying a higher BMI, body fat percent, and body fat mass
than non-PPI users. The BMI of PPI users (M(SD) = 33.2±6.6, Mdn = 30.9) is classified as obese
while the BMI of non-PPI users (M(SD) = 28.3±4.4, Mdn = 27.3) is classified as overweight.46
Because there is an association between BMI and GERD, obesity is commonly seen as a risk
factor contributing to the development of GERD.47,48 Research has indicated that obesity is
associated with a significant 1.5 to 2 times increase in risk of GERD development and this
association has been confirmed utilizing a multichannel intraluminal impedance pH monitoring
test.49-51 The mechanism of this relationship is largely unknown; however, one study suggests
that obesity is associated with a post-prandial transient lower esophageal sphincter relaxation
with subsequent acid reflux.48 Subjects with a higher BMI in the aforementioned study were
more likely to have acid reflux and therefore had a greater reliance on PPIs.

Dietary and Supplemental Intake

PPI users and non-PPI users were not significantly different regarding dietary or
supplemental intake of B vitamins. When dietary and supplemental intakes were combined, the
RDA for vitamin B12, vitamin B6, and folic acid was met. The only vitamin that would affect
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uMMA levels is vitamin B12, and all subjects were ingesting a sufficient amount of vitamin B12
based on the established RDA. There is no reason to suggest that dietary intake or
supplementation had any effect on uMMA results.

Urinary Methylmalonic Acid

The only other study using uMMA to measure vitamin B12 status was conducted by
Lukaszuk et al., which investigated the effect of PPI use on vitamin B12 status in people 22-50
years old. This study and the current study both found that uMMA was not significantly different
between PPI users and non-PPI users.12 The use of uMMA as a biomarker of vitamin B12 status
has been confirmed by various studies.11 No participants were approaching the abnormal level of
uMMA of > 3.8 µg MMA/mg creatinine.12

Conclusion

The results of this study indicate that chronic use of PPIs in people 50-70 years old
recruited for this study did not negatively affect vitamin B12 status as assessed by uMMA levels.
The participants in this study were relatively healthy (other than GERD) with no history of
Crohn’s disease, ulcerative colitis, pernicious anemia, and liver or kidney disease. Future studies
should recruit a larger sample size and target higher risk populations such as those individuals
with malabsorption disorders, liver disease, renal disease, vegans or individuals following a
gluten-free diet. One may also consider recruiting individuals with chronic atrophic gastritis or
individuals over the age of 70.

CHAPTER 6
LIMITATIONS AND FUTURE RESEARCH

Limitations

The current research was limited by a small sample size (n=30). To accommodate the
small sample size, a nonparametric test was required to be utilized, which is not as powerful as a
parametric test such as the paired-samples t-test. Although more recent research has shown the
justification for using the t-test in small sample sizes, the variable being tested must be normally
distributed.52 This was not the case with the uMMA levels among PPI users and non-PPI users,
thus eliminating the ability to use a parametric test.
The PPI users and non-PPI users were also significantly different in regards to three
physical characteristics. The groups were significantly different regarding BMI, body fat percent,
and body fat mass. Ideally, the groups would not be significantly different regarding physical
characteristics. However, the ages of participants were not significantly different between PPI
users and non-PPI users. PPI users were gender- and age-matched within ± 3 years, although
ideally, participants would be age-matched to exactly the same age. Due to difficulty recruiting
participants, this was not feasible and the researchers determined it was appropriate to match age
as closely as possible.
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The current research was also cross-sectional in nature. Researchers were unable to
obtain uMMA levels prior to PPI use to analyze any affect after long-term use of PPIs. This was
not feasible due to time and monetary constraints.

Future Research

A larger sample size would be beneficial for future research to contribute to stronger
statistical power. Studies may be more beneficial in vulnerable populations such as the elderly or
individuals with several co-morbidities. Studies may also be focused towards greater length of
PPI use and evaluation of vitamin B12 status; however, the average length of PPI use of the
current research was 7 years, which is quite long term.

REFERENCES
1. Administration on Aging. Administration for Community Living. US Department of
Health and Human Services. Profile of Older Americans: 2013. Administration of
Community Living Web site. http://www.aoa.gov/AoARoot/Aging_Statistics/
Profile/2013/3.aspx. Published 2013. Accessed July 17. 2014.
2. Achem SR. DeVault KR. Gastroesophageal reflux disease and the elderly. Gastroenterol
Clin N Am. 2014;43:147-160.
3. Yang Y, Metz DC. Safety of proton pump inhibitor exposure. Gastroenterology.
2010;139:1115-1127.
4. Masclee GMC, Sturkenboom MCJM, Kuipers EJ. A benefit-risk assessment of the use of
proton pump inhibitors in the elderly. Drugs Aging. 2014;31:263-282.
5. Saltzman JR, Russell RM. The Aging gut: nutritional issues. Gastroenterol Clin North
Am. 1998;27(2):309-324.
6. Allen, LH. How common is vitamin-B12 deficiency? Am J Clin Nutr.
2009;89(suppl):S693-S696.
7. Pfeiffer CM, Caudill SP, Gunter EW, et al. Biochemical indicators of B vitamin status in
the US population after folic acid fortification results from the National Health and
Nutrition Examination Survey 1999-2000. Am J Clin Nutr. 2005;82:442-450.
8. Wolters M, Strohle A, Hahn A. Cobalamin: a critical vitamin in the elderly. ISRN Prev
Med. 2004;39:1256-1266.
9. Higdon J, Drake VJ, Delage B, et al. Vitamin B12. Linus Pauling Institute: Micronutrient
Information Center Web site. http://lpi.oregonstate.edu/infocenter/vitamins/vitaminB12/.
Published 2000. Updated April 2014. Updated June 4, 2015. Accessed July 2, 2014.
10. Chatthanawaree W. Biomarkers of cobalamin (vitamin B12) deficiency and its
application. J Nutr Health Aging. 2011;15(3):227-231.

50
11. Hill MH, Flatley JE, Barker ME, et al. A vitamin B-12 supplement of 500 µg/d for eight
weeks does not normalize urinary methylmalonic acid or other biomarkers of vitamin B12 status in elderly people with moderately poor vitamin B-12 status. J Nutr.
2013;143:142-147.
12. Lukaszuk JM, Prawitz AD, Shokrani M, et al. Methylmalonic acid levels in non-elderly
adult chronic PPI users. J Hum Nutr Food Sci. 2013;1:1004.
13. Grober U, Kisters K, Schmidt J. Neuroenhancement with vitamin B12 – underestimated
neurological significance. Nutrients. 2013;5:5031-5045.
14. Gultepe M, Ozcan O, Avsar K, et al. Urine methylmalonic acid measurements for the
assessment of cobalamin deficiency related to neuropsychiatric disorders. Clin Biochem.
2003;36:275-282.
15. Hirschowitz BI, Worthington J, Mohnen J. Vitamin B12 deficiency in hypersecretors
during long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther.
2008;27:1110-1121.
16. Den Elzen WPJ, Groeneveld Y, De Ruijter W, et al. Long-term use of proton pump
inhibitors and vitamin B12 status in elderly individuals. Aliment Pharmacol Ther.
2008;27:491-497.
17. Rozgony NR, Fang C, Kuczmarski MF. Vitamin B12 deficiency is linked with long-term
use of proton pump inhibitors in institutionalized older adults: could a cyanocobalamin
nasal spray be beneficial. J Nutr Elder. 2010;29(1):87-99.
18. Dharmarajan TS, Kanagala MR, Murakonda P, et al. Do acid-lowering agents affect
vitamin B12 status in older adults? J Am Med Dir Assoc. 2008;9:162-167.
19. Valuck RJ, Ruscin JM. A case-control study on adverse effects: H2 blocker or proton
pump inhibitor use and risk of vitamin B12 deficiency in older adults. J Clin Epidemiol.
2004;57:422-428.
20. Ito T, Jensen RT. Association of long-term proton pump inhibitor therapy with bone
fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium. Curr
Gastroenterol Rep. 2010;12(6):448-457.
21. Saltzman JR, Kemp JA, Golner BB, et al. Effect of hypochlorhydria due to omeprazole
treatment or atrophic gastritis on protein-based vitamin B12 absorption. J Am Coll Nutr.
1994;13(6):584-591.
22. Abraham NS. Proton pump inhibitors: potential adverse effects. Curr Opin
Gastroenterol. 2012;28:615-620.

51
23. Gropper SS, Smith JL. Advanced Nutrition and Human Metabolism. 6 ed. United States:
Wadsworth Cengage Learning; 2013: 344-360.
th

24. Calabresi PA. Multiple sclerosis and demyelinating conditions of the central nervous
system. In: Goldman L, Schafer AI, ed. Cecil Medicine. 24th ed. Philadelphia, Pa:
Saunders Elsevier; 2011.
25. Howden CW. Vitamin B12 levels during prolonged treatment with proton pump
inhibitors. J Clin Gastroenterol. 2000;30(1):29-33.
26. vanAsselt DZB, de Groot LCPGM, van Staveren WA, et al. Role of cobalamin intake and
atrophic gastritis in mild cobalamin deficiency in older Dutch subjects. Am J Clin Nutr.
1998;68:328-334.
27. Carmel, R. Cobalamin, the stomach, and aging. Am J Clin Nutr. 1997;66:750-759.
28. Carmel, R. Diagnosis and management of clinical and subclinical cobalamin deficiencies:
why controversies persist in the age of sensitive metabolic testing. Biochimie.
2013;95:1047-1055.
29. Solfrizzi V, Panza, F, Capurso A. The role of diet in cognitive decline. J Neurol Transm.
2003;110:95-110.
30. Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia
and Alzheimer’s disease. N Engl J Med. 2002;346:476-483.
31. Norman, EJ. Urinary methylmalonic acid test may have greater value than the total
homocysteine assay for screening elderly individuals for cobalamin deficiency. Clin
Chem. 2004;50(8):1482.
32. Norman EJ, Morrison JA. Screening elderly populations for cobalamin (vitamin B12)
deficiency using the urinary methylmalonic acid assay by gas chromatography mass
spectrometry. Am J Med. 1993;94:589-594.
33. Vogeser M, Muller W, Lorenzi S. External quality assessment of urinary methylmalonic
acid quantification – results of a pilot study. Clin Chem Lab Med. 2007;45(5):695-696.
34. Lindenbaum J, Rosenberg IH, Wilson PWF, et al. Prevalence of cobalamin deficiency in
the Framingham elderly population. Am J Clin Nutr. 1994;60:2-11.
35. Sipponen P, Laxen F, Huotari K, et al. Prevalence of low vitamin B12 and high
homocysteine in serum in an elderly male population: Association with atrophic gastritis
and Helicobacter pylori infection. Scand J Gasatroenterol. 2003;12:1209-1216.

52
36. Mirkazemi C, Peterson GM, Tenni PC, et al. Vitamin B12 deficiency in Australian
residential aged care facilities. J Nutr Health Aging. 2012;16(3):277-280.
37. Loikas, S, Koskinen P, Irjala K, et al. Vitamin B12 deficiency in the aged: a populationbased study. Age and Ageing. 2007;36:177-183.
38. Gill JM, Player MS, Metz DC. Balancing the risks and benefits of proton pump
inhibitors. Ann Fam Med. 2011;9:200-202.
39. Heidelbaugh JJ, Goldberg KL, Inadomi JM. Overutilization of proton pump inhibitors: a
review of cost-effectiveness and risk in PPI. Am J Gastroenterol. 2009;104:S27-S32.
40. Bavishi C, DuPont HL. Systematic review: the use of proton pump inhibitors and
increased susceptibility to enteric infection. Aliment Pharmacol Ther. 2011;34:12691281.
41. Thomson ABR, Sauve MD, Kassam N, et al. Safety of the long-term use of proton pump
inhibitors. World J Gastroenterol. 2010;16(19):2323-2330.
42. Ruscin JM, Page II RL, Valuck RJ. Vitamin B12 deficiency associated with histamine2receptor antagonists and a proton pump inhibitor. Ann Pharmacother. 2002;36:812-816.
43. Marcuard SP, Albernaz L, Khazanie PG. Omeprazole therapy causes malabsorption of
cyanocobalamin (Vitamin B12). Ann Intern Med. 1994;120:211-215.
44. Koop H, Bachem MG. Serum iron, ferritin, and vitamin B12 during prolonged omeprazole
therapy. J Clin Gastroenterol. 1992;14(4):288-292.
45. Harris JE, Boushey C, Bruemmer B, et al. Publishing nutrition research: a review of
nonparametric methods, part 3. J Am Diet Assoc. 2008;108:1488-1496.
46. Charney P, Malone AM. ADA Pocket Guide to Nutrition Assessment. Chicago, IL:
Academy of Nutrition and Dietetics; 2009: 156-157.
47. Corley DA, Kubo A. Body mass index and gastroesophageal reflux disease: a systematic
review and meta-analysis. Am J Gastroenterol. 2006;108:2619-2628.
48. Wu JC, Mui L, Cheung CM, et al. Obesity is associated with increased transient lower
esophageal sphincter relaxation. Gastroenterology. 2007;132:883-889.
49. El-Serang H, Graham DY, Satia JA, et al. Obesity is an independent risk factor for
GERD symptoms and erosive esophagitis. Am J Gastroenterol. 2005;100:1243-1250.
50. El-Serang H. The Association between obesity and GERD: a review of the
epidemiological evidence. Dig Dis Sci. 2008;53:2307-2312.

53
51. Hajar N, Castell DO, Ghomrawi H, et al. Impedance pH confirms the relationship
between GERD and BMI. Dig Dis Sci. 2012;57:1875-1879.
52. deWinter JCF. Using the student’s t-test with extremely small sample sizes. Practical
Assessment, Research & Evaluation. 2013;18(10):1-12.

APPENDIX A
RECRUITMENT FLYER

55

56

APPENDIX B
RECRUITMENT SCRIPT

58
Script for Introductory Remarks
Project: Methylmalonic Acid Levels in Older Adult Chronic PPI Users
Researchers: Dr. Lukaszuk, Dr. Umoren, Dr. Shokrani, and Tashia Warner
Hello. My name is ____________________. I’m calling on behalf of Dr. Lukaszuk and
colleagues who are conducting a study on how the use of stomach acid lowering medications
affect vitamin B12 levels. The potential benefits to you include learning your current vitamin B12
levels and having your lean body mass and body fat percentage measured free of charge. If you
are interested in participating, I will ask you a few questions to determine eligibility and provide
you with more detail about the procedures. Are you interested in participating in this study, and
if so, may I ask you a few screening questions to determine if you are eligible for this study?
If the response is no, participant is not interested.
Thank you. I appreciate your time. Goodbye.
If the response is yes, participant is interested.
Thank you. [Proceed with screening questions.]
Screening Questions
Before we proceed, I have a few questions for you to determine your eligibility.
Are you aged between 55-90 years old?
If response is yes, proceed to next question:
If response is no, participant is not eligible.
Do you eat meat and other animal products?
If response is yes, proceed to next question.
If response is no, participant is not eligible.
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Do you suffer from Crohn’s disease, ulcerative colitis, pernicious anemia, liver disease or
kidney disease?
If response is no, proceed to next question.
If response is yes, participant is not eligible.
Are you taking the medication, metformin?
If response is no, proceed to next question.
If response is yes, participant is not eligible.
Do you have any electronic implants, i.e. pacemakers?
If response is no, proceed to next question.
If response is yes, participant is not eligible.
Are you receiving any intramuscular shots of B12 or using the nasal spray, Nascobal?
If response is no, participant is eligible to participate, proceed to final questions.
If response is yes, participant is not eligible.
Participant is eligible to participant in the study. The final questions serve to assign the eligible
participant to their respective groups.
Have you been taking medication to reduce stomach acid production for at least 1 year?
Examples of these medications include:







Omeprazole (Prilosec, Zegerid)
Lansoprazole (Prevacid/Prevacid I.V./Prevacid 24h/Prevacid Solu-Tab, Zoton)
Dexlansoprazole (Kapidex)
Pantoprazole (Protonix/Protonix I.V.)
Rabeprazole (Aciphex)
Esomeprazole (Nexium/Nexium I.V.)

If response is yes, participant is assigned to treatment group.
If response is no, participant is assigned to control group.

60

If not eligible to participate:
Thank you for your interest and for taking the time to answer our screening questions.
Unfortunately, you currently do not meet the requirements of this study. However, would
you like us to contact you regarding participation in future studies?
If no: Thank you again for your time. Goodbye.
If yes: May I have your email address? Thank you again for your time. Goodbye.
If yes and would like to participate:
Great! We will send you a three day food record. Would you prefer receiving the three
day food record by email or by mail? We will also set a date for you to visit NIU to have
your anthropometric measurements and to supply a urine sample.
[Obtain email or mailing address.]
There are instructions on the three day food record, but I will discuss them briefly with
you as well. We ask that you write down everything you eat and drink for three days.
Remember to include the little things such as condiments, sugar, milk, etc. An example is
the sugar and milk that is added to your coffee. Please try to approximate portion sizes of
each item eaten as best you can. Do not change the way you usually eat and continue to
eat as you normally would. If you have any questions, feel free to contact us via phone or
email at any time. We have these dates and times available for you to schedule your
appointment. What day and time would work best for you?
[Set date and confirm. Collect contact information from participant.]
At this appointment, you sign a consent form, complete a short survey, allow
anthropometrics to be measured, and provide a urine sample.
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Thanks again for your time and for your willingness to participate in this study. We will
send your three day food record out today and we will see you [date]. Contact us if you
have any questions or need to reschedule. Thank you!

APPENDIX C
RECRUITMENT SCREENING FORM
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Screening for Eligibility
PPI/NON-PPI Users
Please fill in the blanks and highlight YES or NO to indicate your choice. Email the completed
form to b12ppistudy@yahoo.com.
NAME: __________________________________
DATE OF BIRTH: ___________________________
AGE: _______________
SEX: ________________
 Crohn’s Disease?
YES or
NO


Ulcerative Colitis?

YES

or

NO



Pernicious Anemia?

YES

or

NO



Use of Metformin?

YES

or

NO



Liver Disease?

YES

or

NO



Kidney Disease?

YES

or

NO



Vegetarian Diet?

YES

or

NO



Use of B12 Injections?

YES

or

NO



Use of B12 Nasal Spray? Example: Nascobal

YES

or

NO



Implanted Device? Example: Pacemaker

YES

or

NO



Use of one of the following medications for at least 1 year? Prilosec, Zegerid, Prevacid,
Kapidex, Protonix, Aciphex, Nexium or any generic drug that ends in –azole.
YES

or

NO

Thank you for completing this questionnaire! You will be contacted of your eligibility shortly.
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Survey for PPI Users
Name: _____________________________________________________
Age: ______________________
Gender: ___________________
Demographics
Which of the following best describes you?
Caucasian: _______
African/African-American: _______
Asian/Asian-American: _________
Hispanic/Latino: ________
Native American: _________
Other: ________________
Lifestyle and Eating Habits
Are you an ex-smoker? Circle One: Yes or
No
Do you currently smoke? Circle One: Yes or
No
If yes, how many cigarettes or cigars do you smoke per day? ____________
_____________________________________________________________
Which of the following diets do you currently follow?
Gluten Free: _________
Lactose Free: _________
No Restrictions: ________
Other: ______________________________
How many meals per day do you eat? _______________________________
How many snacks per day do you eat? _______________________________
How would you best describe your appetite?
Excellent: ________
Good: ___________
Fair: ____________
Poor: ___________
Do you eat red meat? Circle One:
Yes or
No
If yes, how many days per week do you eat red meat? __________________
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Do you eat/drink milk or milk products?
Circle One: Yes or
No
If no, do you eat/drink soy, almond, rice or coconut milk substitute products?
Circle One: Yes or
No
How many days per week do you eat/drink milk products or milk substitute
products? __________________________________________________
Which of the following best describes your exercise activity?
7 days/week: __________
6 days/week: __________
5 days/week: __________
4 days/week: __________
3 days/week: __________
2 days/week: __________
1 day/week: ___________
None: ________________
Which of the following best describes the intensity of your activity?
Sedentary (i.e. normal activities of daily living only): _________
Low (i.e. able to sing while exercising): ______________
Moderate (i.e. conversation possible, but winded): _________
Vigorous (i.e. gasping for breath): __________
How long does your typical exercise session last?
Less than 20 minutes: _______________
20-29 minutes: ____________________
30-39 minutes: ___________________
40-49 minutes: ________________
50-59 minutes: _________________
60 minutes or more: _____________
Not Applicable: ________________
Medication/Supplement Use
What acid suppressant medication are you currently taking? _________________
__________________________________________________________________
__________________________________________________________________
What dosage? _________________________________________________
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Are you currently taking any other medications?
Circle One: Yes or
No
If yes, please list. _______________________________________________
_____________________________________________________________
_____________________________________________________________
_____________________________________________________________
Are you currently taking an oral vitamin and/or mineral supplement? If yes, please
list supplement(s).
__________________________________________________________________
__________________________________________________________________
__________________________________________________________________
Are you currently taking an oral supplemental form of vitamin B12?
Circle One: Yes or
No
If yes, what dosage are you currently taking? _________________________
If yes, how long have you been taking this supplement? ________________
Are you currently taking an oral supplemental form of vitamin B6?
Circle One: Yes or
No
If yes, what dosage are you currently taking? _________________________
If yes, how long have you been taking this supplement? ________________
Are you currently taking an oral supplemental form of folic acid?
Circle One: Yes or
No
If yes, what dosage are you currently taking? _________________________
If yes, how long have you been taking this supplement? ________________
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Survey for Non-PPI Users
Name: _____________________________________________________
Age: ______________________
Gender: ___________________
Demographics
Which of the following best describes you?
Caucasian: _______
African/African-American: _______
Asian/Asian-American: _________
Hispanic/Latino: ________
Native American: _________
Other: ________________
Lifestyle and Eating Habits
Are you an ex-smoker? Circle One: Yes or
No
Do you currently smoke? Circle One: Yes or
No
If yes, how many cigarettes or cigars do you smoke per day? ____________
_____________________________________________________________
Which of the following diets do you currently follow?
Gluten Free: _________
Lactose Free: _________
No Restrictions: ________
Other: ______________________________
How many meals per day do you eat? _______________________________
How many snacks per day do you eat? _______________________________
How would you best describe your appetite?
Excellent: ________
Good: ___________
Fair: ____________
Poor: ___________
Do you eat red meat? Circle One:
Yes or
No
If yes, how many days per week do you eat red meat? __________________
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Do you eat/drink milk or milk products?
Circle One: Yes or
No
If no, do you eat/drink soy, almond, rice or coconut milk substitute products?
Circle One: Yes or
No
How many days per week do you eat/drink milk products or milk substitute
products? __________________________________________________
Which of the following best describes your exercise activity?
7 days/week: __________
6 days/week: __________
5 days/week: __________
4 days/week: __________
3 days/week: __________
2 days/week: __________
1 day/week: ___________
None: ________________
Which of the following best describes the intensity of your activity?
Sedentary (i.e. normal activities of daily living only): _________
Low (i.e. able to sing while exercising): ______________
Moderate (i.e. conversation possible, but winded): _________
Vigorous (i.e. gasping for breath): __________
How long does your typical exercise session last?
Less than 20 minutes: _______________
20-29 minutes: ____________________
30-39 minutes: ___________________
40-49 minutes: ________________
50-59 minutes: _________________
60 minutes or more: _____________
Not Applicable: ________________
Medication/Supplement Use
Are you using any antacid medications that are NOT PPIs?
Circle One: Yes or
No
If yes, what type? _________________________________________
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Are you currently taking any other medications?
Circle One: Yes or
No
If yes, please list. _______________________________________________
_____________________________________________________________
_____________________________________________________________
_____________________________________________________________
Are you currently taking an oral vitamin and/or mineral supplement? If yes, please
list supplement(s).
__________________________________________________________________
__________________________________________________________________
__________________________________________________________________
Are you currently taking an oral supplemental form of vitamin B12?
Circle One: Yes or
No
If yes, what dosage are you currently taking? _________________________
If yes, how long have you been taking this supplement? ________________
Are you currently taking an oral supplemental form of vitamin B6?
Circle One: Yes or
No
If yes, what dosage are you currently taking? _________________________
If yes, how long have you been taking this supplement? ________________
Are you currently taking an oral supplemental form of folic acid?
Circle One: Yes or
No
If yes, what dosage are you currently taking? _________________________
If yes, how long have you been taking this supplement? ________________

